Bio-Rad's Q3 Revenues Increase 2 Percent amid 'Weak' Markets | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market Tuesday a 2 percent increase in its third-quarter revenues year over year, falling short of analysts' consensus estimate.

The Hercules, Calif.-based life sciences and diagnostics products firm brought in total revenues of $471.5 million for the three months ended Sept. 30, compared to revenues of $461.1 million for the third quarter of 2009. Analysts had expected revenues of $476.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.